Skip to main content
main-content

03.06.2019 | Original Research | Ausgabe 8/2019

Journal of General Internal Medicine 8/2019

Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study

Zeitschrift:
Journal of General Internal Medicine > Ausgabe 8/2019
Autoren:
Ph.D. Jill E. Lavigne, Ph.D. Kwan Hur, M.S. Cathleen Kane, Pharm.D. Anthony Au, Ph.D. Todd M. Bishop, Ph.D. Wilfred R. Pigeon
Wichtige Hinweise

Key Points

Questions: What is the comparative safety of medications routinely used to treat insomnia after controlling for history, comorbidities, central nervous system medications, and other factors in patients seen in the VA healthcare system?
Findings: Among Veterans taking new prescriptions of any one medication routinely used to treat insomnia, incidence of suicide attempt was significantly higher among those who started trazodone compared to zolpidem. Benzodiazepines and sedating antihistamines prescribed for sleep were associated with similar risk of suicide attempt as zolpidem
Meaning: These findings provide empirical support for the American Academy of Sleep Medicine 2017 clinical practice guidelines discouraging the use of trazodone as a first-line therapy for insomnia

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Importance

Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence. The Department of Veterans Health Affairs (VA) fills high volumes of inexpensive, over-the-counter sedating antihistamines and older antidepressants in addition to benzodiazepines and zolpidem. Yet little is known about the comparative safety of these agents with regard to suicidal behavior.

Objectives

To assess the comparative effectiveness of the safety of medications routinely used to treat insomnia in VA.

Design

Comparative effectiveness using propensity score-matched samples.

Setting

VA.

Participants

VA patients without any history of suicidal ideation or behavior 12 months prior to first exposure.

Exposures

VA formularies and data were used to identify prescriptions for insomnia. Agents accounting for at least 1% of total insomnia fill volume were < 200 mg trazodone, hydroxyzine, diphenhydramine, zolpidem, lorazepam, diazepam, and temazepam. Exposure was defined as an incident monotherapy exposure preceded by 12 months without any insomnia medications. Subjects with insomnia polypharmacy or cross-overs in the 12 months following first exposure were excluded.

Main Outcomes and Measures

Suicide attempts within 12 months of first exposure.

Results

Three hundred forty-eight thousand four hundred forty-nine subjects met criteria and three well-balanced cohorts by drug class matched to zolpidem were created. After adjusting for days’ supply, mental health history, and pain and central nervous system medication history, hazard ratios (compared to zolpidem) were as follows: (< 200 mg) trazodone (HR = 1.61, 95% CI 1.07–2.43); sedating antihistamines (HR = 1.37, 95% CI 0.90–2.07); and benzodiazepines (HR = 1.31, 95% CI 0.85–2.08).

Conclusions and Relevance

Compared to zolpidem, hazard of suicide attempt was 61% higher with trazodone (< 200 mg). No significant differences in suicide attempt risk were identified between benzodiazepines or sedating antihistamines and zolpidem, respectively. These findings provide the first comparative effectiveness evidence against the use of trazodone for insomnia.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 8/2019

Journal of General Internal Medicine 8/2019 Zur Ausgabe
  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Allgemeinmedizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise